WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 525267
Description: Icofungipen is a novel class of antifungals, beta amino acids, active against Candida species. Icofungipen shows nearly complete oral bioavailability in a variety of species, and its in vivo efficacy indicates its potential for the oral treatment of yeast infections.
MedKoo Cat#: 525267
Chemical Formula: C7H11NO2
Exact Mass: 141.07898
Molecular Weight: 141.17
Elemental Analysis: C, 59.56; H, 7.85; N, 9.92; O, 22.67
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Icofungipen; PLD 118; PLD118; PLD-118; BAY 10-8888; BAY 108888; BAY108888
IUPAC/Chemical Name: 2-Amino-4-methylenecyclopentane-1-carboxylic acid
InChi Key: RKOUGZGFAYMUIO-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H11NO2/c1-4-2-5(7(9)10)6(8)3-4/h5-6H,1-3,8H2,(H,9,10)
SMILES Code: C=C1C[C@H]([C@H](C1)N)C(=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 141.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kiss L, Forró E, Orsy G, Ábrahámi R, Fülöp F. Stereo- and Regiocontrolled Syntheses of Exomethylenic Cyclohexane β-Amino Acid Derivatives. Molecules. 2015 Nov 27;20(12):21094-102. doi: 10.3390/molecules201219749. PubMed PMID: 26633314.
2: Novak P, Tepes P, Ilijas M, Fistrić I, Bratos I, Avdagić A, Hamersak Z, Marković VG, Dumić M. LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. J Pharm Biomed Anal. 2009 Aug 15;50(1):68-72. doi: 10.1016/j.jpba.2009.03.017. Epub 2009 Mar 25. PubMed PMID: 19410412.
3: Ferrer E. Spotlight on targeting aminoacyl-tRNA synthetases for the treatment of fungal infections. Drug News Perspect. 2006 Jul-Aug;19(6):347-8. PubMed PMID: 16971970.
4: Hasenoehrl A, Galic T, Ergovic G, Marsic N, Skerlev M, Mittendorf J, Geschke U, Schmidt A, Schoenfeld W. In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob Agents Chemother. 2006 Sep;50(9):3011-8. PubMed PMID: 16940096; PubMed Central PMCID: PMC1563551.
5: Yeates C. Icofungipen (PLIVA). Curr Opin Investig Drugs. 2005 Aug;6(8):838-44. Review. PubMed PMID: 16121691.
6: Petraitiene R, Petraitis V, Kelaher AM, Sarafandi AA, Mickiene D, Groll AH, Sein T, Bacher J, Walsh TJ. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92. PubMed PMID: 15855534; PubMed Central PMCID: PMC1087633.
7: Parnham MJ, Bogaards JJ, Schrander F, Schut MW, Oresković K, Mildner B. The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro. Biopharm Drug Dispos. 2005 Jan;26(1):27-33. PubMed PMID: 15593345.
8: Petraitis V, Petraitiene R, Kelaher AM, Sarafandi AA, Sein T, Mickiene D, Bacher J, Groll AH, Walsh TJ. Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob Agents Chemother. 2004 Oct;48(10):3959-67. PubMed PMID: 15388459; PubMed Central PMCID: PMC521932.
9: Dorrell S. Overcoming drug-resistant yeast infections. Drug Discov Today. 2002 Mar 15;7(6):332-3. PubMed PMID: 11893534.
10: Ziegelbauer K, Babczinski P, Schönfeld W. Molecular mode of action of the antifungal beta-amino acid BAY 10-8888. Antimicrob Agents Chemother. 1998 Sep;42(9):2197-205. PubMed PMID: 9736535; PubMed Central PMCID: PMC105775.
11: Ziegelbauer K. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob Agents Chemother. 1998 Jul;42(7):1581-6. PubMed PMID: 9660987; PubMed Central PMCID: PMC105649.